X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with SHASUN PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SHASUN PHARMA PLETHICO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x -1.1 123.9 - View Chart
P/BV x 0.0 8.5 0.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PLETHICO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SHASUN PHARMA
Mar-14
PLETHICO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs39594 419.2%   
Low Rs3146 68.6%   
Sales per share (Unadj.) Rs604.4214.2 282.2%  
Earnings per share (Unadj.) Rs32.55.3 608.7%  
Cash flow per share (Unadj.) Rs51.315.8 324.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs473.653.3 887.8%  
Shares outstanding (eoy) m34.0856.62 60.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 108.0%   
Avg P/E ratio x6.613.1 50.1%  
P/CF ratio (eoy) x4.24.4 94.0%  
Price / Book Value ratio x0.51.3 34.3%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m7,2623,958 183.5%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5962,164 73.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59812,127 169.9%  
Other income Rs m386229 168.4%   
Total revenues Rs m20,98412,356 169.8%   
Gross profit Rs m2,8181,009 279.2%  
Depreciation Rs m642594 108.2%   
Interest Rs m1,593415 383.8%   
Profit before tax Rs m969230 421.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-73 190.3%   
Profit after tax Rs m1,107302 366.4%  
Gross profit margin %13.78.3 164.4%  
Effective tax rate %-14.3-31.7 45.1%   
Net profit margin %5.42.5 215.7%  
BALANCE SHEET DATA
Current assets Rs m18,8776,884 274.2%   
Current liabilities Rs m11,8968,456 140.7%   
Net working cap to sales %33.9-13.0 -261.5%  
Current ratio x1.60.8 194.9%  
Inventory Days Days3662 58.3%  
Debtors Days Days198108 183.9%  
Net fixed assets Rs m9,8614,970 198.4%   
Share capital Rs m341113 300.7%   
"Free" reserves Rs m12,3312,875 428.9%   
Net worth Rs m16,1393,020 534.4%   
Long term debt Rs m4,7061,817 258.9%   
Total assets Rs m33,14613,347 248.3%  
Interest coverage x1.61.6 103.5%   
Debt to equity ratio x0.30.6 48.5%  
Sales to assets ratio x0.60.9 68.4%   
Return on assets %8.15.4 151.6%  
Return on equity %6.910.0 68.6%  
Return on capital %12.313.3 92.2%  
Exports to sales %21.446.4 46.1%   
Imports to sales %15.214.2 106.9%   
Exports (fob) Rs m4,4025,622 78.3%   
Imports (cif) Rs m3,1361,728 181.5%   
Fx inflow Rs m4,4025,843 75.4%   
Fx outflow Rs m3,1842,173 146.5%   
Net fx Rs m1,2193,669 33.2%   
CASH FLOW
From Operations Rs m2,437398 613.0%  
From Investments Rs m-6,265-1,635 383.2%  
From Financial Activity Rs m2,4901,309 190.3%  
Net Cashflow Rs m-1,33771 -1,878.0%  

Share Holding

Indian Promoters % 82.7 39.2 211.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 3.6 119.4%  
FIIs % 5.5 17.6 31.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 39.6 18.9%  
Shareholders   10,665 20,750 51.4%  
Pledged promoter(s) holding % 85.7 12.3 697.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   VENUS REMEDIES  MERCK LTD  SANOFI INDIA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS